06 Aug: 2019

  • Launched five non-prescription Consumer Health brands into SA market.
  • Signed exclusive partnership with Enzymatica for the commercialization of ColdZyme in Australia and New Zealand.

06 Aug: 2018

  • Entered strategic collaboration with Pharma Dynamics to commercialize NEXA in SA.
  • Established strategic JV in UK for pan EU sales footprint and RnD cooperation
  • First MA approved in UK (Gabapentin)
  • Acquired Eden Pharmaceuticals Pvt Ltd in Australia

06 Aug: 2017

  • Opened office in Cyprus and United Kingdom.
  • Established ABEX Consumer Division and signed exclusive rights to commercialize Nasaleze in SA.

06 Aug: 2016

  • Signed Strategic Distribution Agreement with Clicks (Unicorn) Pharmacies.
  • First biosimilar Enoxaparin approved in EU and licensed out.

06 Aug: 2012

  • One of the first Quetiapine generics launched in South Africa.
  • Second to market with Sildenafil.
  • First major tender buyout awarded by DoH.